		* a	etna™
AETNA BETTER	HEALTH®		
Coverage Policy	//Guideline		
	Dry Eye Disease Agents		
Name:	(Cequa, Eysuvis, Miebo, Cyclosporine 0.	05% Page:	1 of 3
	Ophthalmic Emulsion vial, Tyrvaya, Vevy	re, Xiidra)	
Effective Date:	4/4/2025	Last Review Date:	03/14/2025
Applies to:	⊠Illinois		

Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for dry eye disease agents under the patient's prescription drug benefit.

Description:

FDA-approved Indications

Cequa

Cequa ophthalmic solution is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Eysuvis

Eysuvis is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Miebo

Miebo (perfluorohexyl octane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Restasis

Restasis (cyclosporine 0.05% ophthalmic emulsion vial) is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

Tyrvaya

Tyrvaya (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease.

Vevye

Vevye is indicated for the treatment of the signs and symptoms of dry eye disease.

Xiidra

Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Applicable Drug List:

<u>Non-Preferred Agents</u>: Cyclosporine 0.05% Ophthalmic Emulsion Vial Cequa Eysuvis Miebo Tyrvaya Vevye Xiidra

		♦a	etna™
AETNA BETTER	HEALTH®		
Coverage Policy	//Guideline		
	Dry Eye Disease Agents		
Name:	(Cequa, Eysuvis, Miebo, Cyclosporine 0.	05% Page:	2 of 3
	Ophthalmic Emulsion vial, Tyrvaya, Vevy	ve, Xiidra)	
Effective Date:	4/4/2025	Last Review Date:	03/14/2025
Applies to:	⊠Illinois		

Policy/Guideline:

Initial Coverage Criteria

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion, Tyrvaya, Vevye, or Xiidra.
- The patient has experienced an inadequate treatment response, intolerance to, or a contraindication that would prohibit a trial to an artificial tears' product

Short Term Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when the following criteria is met:

- The request is for Eysuvis AND the following criteria is met:
 - The requested drug is being prescribed for short-term use (up to two weeks).
 - The patient has experienced an inadequate treatment response, intolerance to, or a contraindication that would prohibit a trial to an artificial tears' product

Continuation of Therapy

Dry Eye Disease

Authorization may be granted when the requested drug is being prescribed for the treatment of dry eye disease when ALL of the following criteria are met:

- The request is for Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion, Tyrvaya, Vevye, or Xiidra.
- The patient achieved or maintained improvement in their signs and symptoms of dry eye disease from baseline (e.g., ocular irritation, redness, mucous discharge, reduced visual function, ocular surface damage, reduced tear production).

Short Term Dry Eye Disease


All patients (including new patients) requesting authorization for continuation of therapy for Eysuvis must meet ALL requirements in the initial coverage criteria section.

Approval Duration and Quantity Restrictions:

Approval Duration:

- Cequa, Miebo, Cyclosporine 0.05% Ophthalmic Emulsion, Tyrvaya, Vevye, Xiidra (Dry eye disease): 12 months
- Eysuvis (Short term dry eye disease): 3 months

Quantity Level Limit:



Drug	Limit	
Cequa (cyclosporine ophthalmic soln)	60 vials / 30 days	
Miebo (perfluorohexyl octane ophthalmic soln)	1 multi-dose bottle (3 mL) / 30 days	
cyclosporine ophthalmic emlsn	60 vials / 30 days	
Tyrvaya (varenicline nasal spray soln)	2 nasal spray bottles (8.4 mL) / 30 days	
Vevye (cyclosporine ophthalmic soln)	1 multi-dose bottle (2 mL) / 30 days	
Xiidra (lifitegrast ophthalmic soln)	60 containers (1 carton) / 30 days	

For short-term acute use.

Drug	Limit
Eysuvis (loteprednol etabonate ophthalmic susp	2 bottles (16.6 mL) / 90 days
0.25%)	

References:

- 1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; July 2022.
- 2. Eysuvis [package insert]. Fort Worth, TX: Alcon Laboratories, Inc.; November 2023.
- 3. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc.; January 2024.
- 4. Restasis [package insert]. Irvine, CA: Allergan, Inc; September 2024.
- 5. Restasis Multidose [package insert]. Irvine, CA: Allergan, Inc; September 2024.
- 6. Tyrvaya [package insert]. Princeton, NJ: Oyster Point Pharma, Inc.; September 2024.
- 7. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC.; November 2023.
- 8. Xiidra [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; June 2020.
- 9. Lexicomp Online, AHFS DI (Adult and Pediatric Online. Waltham, MA: UpToDate, Inc.; 2024. https://online.lexi.com. Accessed October 16, 2024.
- 10. Micromedex[®] (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: https://www.micromedexsolutions.com/ (cited: 10/16/2024).
- 11. Akpek EK, Amescua G, Farid M, et al. Dry Eye Syndrome Preferred Practice Pattern. Ophthalmology. 2019;126(1): P286-P334.
- 12. Pharmacy Auditing and Dispensing Job Aid: Billing Other Dosage Forms. Centers for Medicare and Medicaid Services. December 2015.